Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC)
jumped 3.2% in the afternoon session after it reported strong third-quarter financial results that surpassed expectations and raised its full-year guidance. The company's revenue for the quarter reached $192.9 million, a 30.7% increase from the same period last year, beating analysts' projections by approximately $8.5 million. Furthermore, iRhythm significantly narrowed its losses, reporting an adjusted loss per share of $0.06, a substantial improvement from a loss of $1.26 per share in the same quarter of the previous year and well ahead of analysts' estimates. In light of the strong performance, the company increased its full-year 2025 revenue forecast to a midpoint of $737.5 million.
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 30.7% year on year to $192.9 million. The company’s full-year revenue guidance of $737.5 million at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP loss of $0.06 per share was 78.9% above analysts’ consensus estimates.
Medical technology company iRhythm Technologies (NASDAQ:IRTC) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 30.7% year on year to $192.9 million. The company’s full-year revenue guidance of $737.5 million at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP loss of $0.06 per share was 78.9% above analysts’ consensus estimates.
Medical technology company iRhythm Technologies (NASDAQ:IRTC)
will be announcing earnings results this Thursday after market close. Here’s what you need to know.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Looking back on patient monitoring stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped returns as the industry’s six-month gain of 6.5% has lagged the S&P 500’s 24.7% climb.
A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.
IRTC stock combines strong technical trends with accelerating fundamentals, aligning with Mark Minervini's high-growth strategy for potential continued gains.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Growth boosts valuation multiples, but it doesn’t always last forever.
Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
